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Abstract
Introduction: Increasing rates of multi-resistant bacteria are a major problem in the treatment of critically ill
patients. Furthermore, conventional antibiotics lead to the release of bacterial derived membrane parts initiating
pro-inflammatory cascades with potential harm to the patient. Antimicrobial peptides (AMP) may kill bacteria
without releasing pro-inflammatory factors. Thus, we compared three newly developed synthetic anti-
lipopolysaccharide peptides (SALPs) with a broader range of efficacy to suppress cytokine release in plasma and
CD14 mRNA expression in organ tissue in a murine, polymicrobial sepsis model.
Methods: A randomized, experimental trial was conducted in an animal research facility. Male NMRI mice (n = 90;
8- to 12-weeks old) were randomized to the following six groups: (i) sham operation and parenteral vehicle (NaCl
0.9%) administration (sham); (ii) cecal ligation and puncture (CLP) and vehicle infusion (sepsis-control), (iii) CLP and
polymyxin B infusion (polyB), or (iv to vi) CLP and infusion of three different synthetic antimicrobial peptides
Peptide 19-2.5 (Pep2.5), Peptide 19-4 (Pep4) or Peptide 19-8 (Pep8). All animals underwent arterial and venous
catheterization for hemodynamic monitoring 48 hours prior to CLP or sham-operation. Physical appearance and
behavior (activity), plasma cytokine levels, and CD14 mRNA expression in heart, lung, liver, spleen and kidney tissue
were determined 24 hours after CLP or sham operation.
Results: Only Pep2.5 significantly enhanced the activity after CLP, whereas none of the therapeutic regimens
elevated the mean arterial pressure or heart rate. The strongly elevated IL-6, IL-10 and monocyte chemoattractant
protein serum levels in septic animals were significantly reduced after Pep2.5 administration (P < 0.001, P < 0.001,
and P < 0.001, respectively). Similarly, Pep2.5 significantly reduced the sepsis-induced CD14 mRNA expression in
heart (P = 0.003), lung (P = 0.008), and spleen tissue (P = 0.009) but not in kidney and liver.
Conclusions: Structurally variable SALPs exhibit major differences in their anti-inflammatory effect in vivo.
Continuous parenteral administration of Pep2.5 is able to reduce sepsis-induced cytokine release and tissue
inflammation.
Introduction
Despite intense effort in basic and clinical research the
morbidity and mortality of sepsis and septic shock have
remained high. The increase in the resistance pattern of
many bacterial blood stream isolates against the most
commonly used antibiotics during the past years further
hampers adequate clinical management. In recent years
the number of multiresistant bacteria isolates has
increased and triggered the implementation of an Inter-
agency Task Force on Antimicrobial Resistance (Centers
for Disease Control and Prevention, USA). New thera-
peutic strategies to combat severe infections are, there-
fore, urgently needed.
Conventional anti-infective agents may kill bacteria
but at the same time release bacteria-derived agents,
such as lipopolysaccharide (LPS) or lipoprotein (LP),
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hence causing the devastating consequences of the pro-
inflammatory cascades in severe sepsis and septic shock.
Antimicrobial peptides (AMP) may kill bacteria without
releasing pro-inflammatory factors, but their application
may be impeded by high toxicity, hemolysis, nephrotoxi-
city and neurotoxicity [1]. Therefore, the challenge is to
develop synthetic peptide-based drugs on the basis of
naturally occurring AMPs in order to treat septic
patients effectively without causing harm.
A new series of peptides of amino acid lengths in the
range 17 to 23 was developed to adapt to the physico-
chemistry of the lipid A part of endotoxins. The struc-
ture of these peptides is based on the LPS-binding
domain of the Limulus anti-LPS factor as a template
and was modified with respect to its capacity to bind
and neutralize LPS [2-4]. In sepsis patients this may be
an advantage since antibiotics may accelerate the release
of pro-inflammatory components increasing the severity
of disease [5,6].
These newly designed synthetic anti-lipopolysacchar-
ide peptides (SALPs) with decreased toxicity and a
broader range of efficacy are able to neutralize LPS-
mediated effects at different degrees in vitro as well as
in vivo [4,7]. In particular, SALPs change the LPS struc-
ture into a multi-lamellar structure accompanied by
large increases in aggregate size. Furthermore, strong
Coulomb interaction between peptide (positive charges)
and LPS (negative charges) influence the incorporation
of the peptides into the LPS bilayer [4,7].
We hypothesized that our newly developed SALPs are
well tolerated when infused intravenously (i.v.) in thera-
peutic amounts. Furthermore, inflammation indicated by
cytokines in plasma and CD14 expression in organ tis-
sue should be decreased in a murine model of polymi-
crobial sepsis.
Materials and methods
Catheterization
After permission of the local animal protection authori-
ties (LANUV, NRW, Germany: Az 8.87-50.10.35.09.044)
all mice (male NMRI mice (n = 90, body weight 38 ± 3
g) underwent a catheterization procedure. Under general
anesthesia (isoflurane 1% to 2% in oxygen/air mix with a
FiO2 of 0.3) spontaneously breathing animals were fixed
in the prone position. The right neck vessels were
exposed under sterile conditions after local anesthesia
with 0.2 ml lidocaine 2% (Astra Zeneca, Wedel, Ger-
many) and a central vein catheter (CVC; self-made
using sterilized polyethylene tubing with an outer dia-
meter of 0.61 mm) was implanted 1 cm deep in the
jugular vein enabling continuous i.v. administration of
fluids and drugs throughout the experiment. The CVC
was tunneled to the back of each mouse and guided
through a flexible plastic tube (Drainobag 40, B.Braun,
Melsungen, Germany) to prevent bite damage. A 27G
cannula was inserted into the CVC to connect the CVC
to the syringe pump. In addition, an arterial transmitter
(PA-C10, Data Sciences International, St. Paul, MN,
USA) was implanted to measure heart rate (HR) and
mean arterial pressure (MAP). The catheter consisted of
a transmitter unit and a gel-filled tube which was intro-
duced and fixed in the right carotid artery. The trans-
mitter unit was implanted subcutaneously in the
abdominal region. Subsequently, after further local infil-
tration with lidocaine, the neck was closed by single
suture and the mouse transferred back into the cage to
rest for 48 hours prior to the induction of sepsis by
cecal ligation and puncture (CLP). To prevent hypother-
mia all animals were kept on a heating pad throughout
the surgical procedure.
Sepsis induction
General and local anesthesia for CLP was performed as
described above. Under sterile conditions a midline
laparatomy of 1 cm was performed. The cecum was
identified, subtotal ligated approximately 1 cm away
from its base and afterwards twice perforated with an
18G needle. Feces were protruded to assure the perfora-
tions were opened. Then the cecum was replaced and
the abdominal cavity was closed by single suture. The
animal was transferred to the cage and reconnected
with the i.v.-line to the syringe pump at a rate of 100
μl/hour. All animals were killed after 24 hours. The
entire experimental course is depicted in Figure 1.
The animals were randomly assigned to one of six
groups:
1. Sepsis-control (N = 15): sepsis induction and vehi-
cle (NaCl 0.9%) infusion
2. Sham (N = 15): sham operation (laparotomy with-
out cecal ligation) and vehicle infusion
3. PolyB (N = 15): CLP sepsis with polymyxin B infu-
sion (1.2 μg/hour Polymyxin B in NaCl 0.9%)
4. Pep 2.5 (N = 15): CLP sepsis with peptide 19-2.5
(Pep 2.5) infusion (2.0 μg/hour peptide in NaCl 0.9%)
Catheteri  - 
zation  
Recovery  CLP  
45 min  48  hrs  10 min  
Sepsis  
24   hrs  
Sampling
Vital  data
Figure 1 Course of experimental procedure. At the end of the
observation vital data were recorded and blood and organ tissue
were sampled. CLP, cecal ligation and puncture.
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5. Pep 4 (N = 15): CLP sepsis with peptide 19-4 (Pep 4)
infusion (pep 4, 2.0 μg/hour peptide in NaCl 0.9%)
6. Pep 8 (N = 15): CLP sepsis with peptide 19-8 (Pep 8)
infusion (2.0 μg/hour peptide in NaCl 0.9%).
Polymyxin B, considered as the most potent anti-
endotoxin agent, was infused in group three to deter-
mine LPS-neutralizing effects. The latter three groups
were treated with the SALPs. The dose of the peptides
had been evaluated in preceding experiments, combin-
ing best decrease in pro-inflammatory cytokines without
side effects.
All animals received a bolus of 200 μl NaCl 0.9% when
transferred to the cage. One animal in the sepsis-control
and two animals each in the other groups were excluded
before analysis due to loss of CVC or bite damage to the
CVC.
Vital data measurements
The average of the last five measurements of HR and
MAP by the arterial transmitter was recorded after
24 hours of sepsis. The physical activity of the mice was
recorded independently by two of the investigators who
were blinded to treatment before sampling. They used a
predefined scoring system ranging from 1 (healthy) to 5
(agony). This scoring system is based on rating physical
activity and food intake (see Table 1) using spontaneous
activity of the mice, reaction to exogenous stimuli and
spontaneous food intake to differ between the grades 1 to
5 [8].
Sampling
After 24 hours of sepsis, the animals were anesthetized,
brought to a prone position and the abdomen and thorax
were opened. Blood was sampled in pre-citrated syringes
and, after centrifugation, plasma samples were frozen fol-
lowing the manufacturers guidelines until measurement.
Directly after killing the animal under general anesthesia
by cervical dislocation, heart, liver, lung, kidney and
spleen were harvested. All organ tissues were snap-frozen
in liquid hydrogen until further processing.
Laboratory measurements
RNA was extracted from frozen tissue (RNeasy Mini Kit,
Qiagen, Hilden, Germany), reverse transcripted to
cDNA (Quanti Tec, Rev Transcription Kit, Qiagen) and
analyzed by real-time-PCR (RT2 real-time SYBR green/
rROX PCR master Mix, PA-012, Biorad, Hercules, CA,
USA) with a mouse specific primer to CD14 (biomers,
Ulm, Germany) using a 7300 Real-time PCR-System
(Applied Biosystems, Carlsbad, CA, USA). Due to finan-
cial restrictions, we randomly assigned 10 out of 15
samples for PCR diagnosis of CD14 of all organs. PCR
was performed using 40 ng of cDNA and standard PCR
protocols in 96-well PCR plates (ABgene, Epsom, UK)
containing 15 μl reaction/well with ReadyToGo PCR
beads (Amersham, Braunschweig, Germany). PCR pri-
mers were as follows: CD14: 5’-CAG AAT CTA CCG
ACC ATG GAG-3’ (forward), 5’-GGA ACA ACT TTC
CTC GTC TAG C-3’ (reverse). As a control we used
beta-actin (actb) with the following primer: 5’-GCT
CTT TTC CAG CCT TCC TT-3’ (forward), 5’-CGG
ATG TCA ACG TCA CAC TT-3’ (reverse). Both pri-
mers were designed using a freely accessible source [9].
The following conditions were used: 95°C for 3 minutes,
then 40 cycles at 95°C for 30 seconds, 57°C for 30 sec-
onds and 72°C for 30 seconds.
Determination of IL-6, IL-10 and monocyte chemoat-
tractant protein-1 (MCP-1) was performed using a cyto-
metric bead array (CBA, BD Biosciences, Heidelberg,
Germany). The CBA consists of bead populations with
distinct fluorescence intensities with specific capture
antibodies. These bead populations were quantitatively
measured using a flow cytometer. We have chosen IL-6
and IL-10 as pro- and anti-inflammatory cytokines
released by monocytes, macrophages and neutrophils.
Additionally, MCP-1 was measured as a chemotactic
agent for monocytes and macrophages. These three mea-
sures are related to the signal transduction by the CD14-
receptor via the Toll-like receptor (TLR) complex.
Peptides
The SALP-peptides were synthesized with an amidated
C terminus by the solid-phase peptide synthesis techni-
que in an automatic peptide synthesizer (model 433A;
Applied Biosystems) on Fmoc-Rink amide resin, accord-
ing to procedures described earlier [7]. The amino acid
sequences of the three peptides, Pep 2.5, Pep 4, and Pep
8, used here are shown in Table 2.
Table 1 Scoring system to measure physical activity of mice [8].
Grade Quality Criteria
1 Very active Strong, curious, quick movements, normal food intake
2 Active Strong, curious, single occasional interruptions in activity, normal food intake
3 Less active Adequate response to environment, frequent interruptions in activity, slightly decreased food intake
4 Slow Sleepy, slow activity, severely decreased food intake
5 Lethargic No activity, motionless, no food intake
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Statistical analysis
Differences in cytokine measures between groups after
24 hours were evaluated by the Kruskal-Wallis test fol-
lowed by a Bonferroni-corrected Wilcoxon Rank-sum test
using SPSS Statistics 20.0 for Windows (SPSS Inc. Chi-
cago, Illinois, USA). The PCR-derived data were analyzed
using a relative expression software tool (REST) perform-
ing a randomization test. This tool avoids assumptions on
distributions and applies a pair wise fixed reallocation ran-
domization test© which reallocates control and sample
groups (= pair wise fixed reallocation). The expression
ratios are calculated on the basis of the mean crossing
point (CP) values for reference and target genes [10]. All
data are given as mean ± SD unless otherwise indicated.
P < 0.05 was considered significant.
Based on previous experiments in human mononuclear
cells [7] we assumed a reduction of pro-inflammatory
cytokines of at least 30% by application of Pep 2.5 and a
weaker effect in the other groups. A total sample size of at
least 90 animals was necessary in order to achieve a power
of at least 90%.
Results
Activity and vital parameters
The activity of mice in the sham-, Pep 2.5- or polymyxin
B-treated groups was significantly higher (each P < 0.001;
Table 3) compared to the sepsis-control group 24 hours
after CLP. Animals treated with Pep 4 and Pep 8 showed
no differences.
There were no significant differences in HR between
the treatment groups, although HR was significantly
higher in the sham group compared to sepsis-control
mice (P = 0.016; Table 3). Therapy with Pep 2.5
resulted in a non-significantly higher HR (P = 0.082,
Table 3). The MAP showed no significant differences
(Table 3).
Plasma cytokines
IL-6 was increased in the sepsis-control group and sig-
nificantly decreased in the Pep 2.5-group compared to
the sepsis-control group (P < 0.001). Treatment with
polyB and Pep 4 and Pep 8 did not reduce IL-6 release
(Figure 2).
IL-10 was significantly decreased in the Pep 2.5 group
(P = 0.002) but not in the Pep 4 (P = 0.111), polyB (P =
0.11) or Pep 8 (P = 0.073) groups compared to the sep-
sis-control group (Figure 2). Likewise, the MCP-1 level
was significantly reduced in the Pep 2.5 group (P <
0.001), but not in the polyB (P = 0.70), Pep 4 (P =
0.183) or Pep 8 (P = 0.718) groups compared to the sep-
sis-control group (Figure 2).
Gene expression
CD14-expression in heart tissue was 3.5 ± 1.8 (mean ±
SEM) fold higher in the sepsis-control compared to the
sham group (P < 0.05). CLP resulted in a non-significant
2.0 ± 1.0 fold gene regulation in the polyB group and
1.5 ± 0.9 in the Pep 2.5-group, whereas both Pep 4 and
Pep 8 showed a significant up-regulation of CD14 (4.5 ±
2.9; P < 0.05 and 4.9 ± 2.7; P < 0.05) compared to the
sham group. Only the Pep 2.5-group had significantly
decreased CD14 expression compared to the control
(P = 0.003; Figure 3).
In lung tissue the pattern of CD14 expression after
treatment was similar to that in the heart. The highest
expression was detected in the sepsis-control (7.4 ± 3.5;
P < 0.05) compared to the sham group. The PolyB group
had a non-significant increase (5.4 ± 2.4). Pep 2.5 treat-
ment resulted in a 1.9 ± 0.9 fold expression, thus signifi-
cantly decreased compared to the sepsis-control group
(P = 0.008). Both the Pep 4 and Pep 8 groups showed a
comparable non-significant increase of CD14 (6.0 ± 3.5
and 5.6 ± 3.6, respectively) (Figure 4).
In spleen we detected maximum CD14 expression in
the sepsis-control (9.1 ± 6.7; P < 0.05) compared to the
sham group (Figure 5). Significantly increased levels com-
pared to the sham animals were found in the polyB, Pep
4 and Pep 8 groups (polyB: 6.3 ± 3.8; Pep 4: 3.7 ± 2.7;
Pep 8: 3.8 ± 2.9; all P < 0.05). Pep 2.5 treatment resulted
in a significantly decreased CD14 expression compared
to sepsis-control (2.3 ± 1.7; P = 0.009).
Table 2 Sequences of the synthetic anti-LPS peptides and
molecular weights.
Peptide Sequence Molecular weight
Pep19-2.5 GCKKYRRFRWKFKGKFWFWG 2711
Pep19-4 GKKYRRFRWKFKGKWFWFG 2750
Pep19-8 GRRYKKFRWKFKGRWFWFG 2636
Table 3 Activity index, mean arterial pressure and heart rate after 24 hours of sepsis.
Sham Sepsis-control polyB Pep 2.5 Pep 4 Pep 8
Activity index (points) 1.1 ± 0.3a 4.4 ± 0.8 3.2 ± 0.5a 2.5 ± 0.7a 4.0 ± 0.8 4.1 ± 0.7
Mean arterial pressure (mmHg) 149 ± 40 126 ± 65 100 ± 27 97 ± 38 92 ± 49 86 ± 29
Heart rate (1/minute) 485 ± 197b 310 ± 88 364 ± 140 434 ± 196 297 ± 108 354 ± 125
aP < 0.001 versus control; bP < 0.05 versus control. Activity index ranges from 1 (best activity) to 5 (agony). Sham, sham operation with vehicle infusion; Sepsis-
control, sepsis with vehicle infusion; polyB, sepsis with PolymyxinB infusion; Pep 2.5, sepsis with peptide 19-2.5 infusion; Pep 4, Sepsis with peptide 19-4 infusion;
Pep 8, sepsis with peptide 19-8 infusion; Data given as mean ± SD
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The regulation of CD14 in liver tissue was significantly
increased in all groups compared to sham treated mice
(all P < 0.05). The sepsis-control and polyB groups
showed comparable results (25.1 ± 16.0 and 24.1 ± 16.4,
respectively; Figure 6). Treatment with Pep 2.5 resulted
in 12.8 ± 7.7 fold expression and was not significantly
different compared to control (P = 0.15). After Pep 4
infusion CD14 expression in liver tissue was 16.8 ± 13.9
and after Pep 8 infusion it was 13.6 ± 11.3 (Figure 6).
Figure 2 Plasma cytokines after 24 hours of sepsis. Blue columns =
Interleukin-6; green columns = Interleukin-10; beige columns =
Monocyte chemoattractant protein-1; sepsis-control (N = 14) = Sepsis
with vehicle infusion; Sham (N = 13) = Sham operation with vehicle
infusion; polyB (N = 13) = Sepsis with PolymyxinB infusion; Pep 2.5 (N =
13) = Sepsis with peptide 19-2.5 infusion; Pep 4 (N = 13) = Sepsis with
peptide 19-4 infusion; Pep 8 (N = 13) = Sepsis with peptide 19-8 infusion;
Data given as box-and-whisker depicting smallest and largest
observation, median ± interquartile range (box); * P < 0.01 versus control.
Figure 3 CD14 expression in heart tissue after 24 hours of
sepsis. Sham (N = 10) = Sham operation with vehicle infusion;
Sepsis-control (N = 10) = Sepsis with vehicle infusion; polyB (N =
10) = Sepsis with PolymyxinB infusion; Pep 2.5 (N = 10) = Sepsis
with peptide 19-2.5 infusion; Pep 4 (N = 10) = Sepsis with peptide
19-4 infusion; Pep 8 (N = 10) = Sepsis with peptide 19-8 infusion;
Data given as mean ± SEM; *P < 0.05 versus sham. SEM, standard
error of the mean.
Figure 4 CD14 expression in lung tissue after 24 hours of sepsis.
Sham (N = 10) = Sham operation with vehicle infusion; Sepsis-control
(N = 10) = Sepsis with vehicle infusion; polyB (N = 10) = Sepsis with
PolymyxinB infusion; Pep 2.5 (N = 10) = Sepsis with peptide 19-2.5
infusion; Pep 4 (N = 10) = Sepsis with peptide 19-4 infusion; Pep 8 (N
= 10) = Sepsis with peptide 19-8 infusion; Data given as mean ± SEM;
*P < 0.05 versus sham. SEM, standard error of the mean.
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Figure 5 CD14 expression in spleen tissue after 24 hours of
sepsis. Sham (N = 10) = Sham operation with vehicle infusion; Sepsis-
control (N = 10) = Sepsis with vehicle infusion; polyB (N = 10) = Sepsis
with PolymyxinB infusion; Pep 2.5 (N = 10) = Sepsis with peptide 19-
2.5 infusion; Pep 4 (N = 10) = Sepsis with peptide 19-4 infusion; Pep 8
(N = 10) = Sepsis with peptide 19-8 infusion; Data given as mean ±
SEM; *P < 0.05 versus sham. SEM, standard error of the mean.
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The up-regulation of kidney derived CD14 was signifi-
cantly increased in all groups (P < 0.05). Compared to
the sham group, the sepsis-control group showed a
27.1 ± 17.8 fold increase. In the polyB group there was
a significant up-regulation of 15.5 ± 9.2. All peptide
treated groups revealed significantly higher CD14
expression (Pep 2.5: 8.3 ± 5.3; Pep 4: 6.6 ± 3.9; Pep 8:
7.0 ± 4.1), but showed no significant differences com-
pared to the control (Figure 7).
Discussion
In a model of early murine sepsis, we demonstrate that
infusion of the newly synthesized Pep 2.5 is able to
decrease pro-inflammatory plasma cytokine release and
to decrease CD14 mRNA tissue expression compared to
untreated controls.
Naturally occurring AMPs are capable of neutralizing
microbial immunostimulatory cell wall constituents such
as LPS. Through binding to LPS they change the aggre-
gate structure of LPS, thereby preventing the binding to
LPS-binding protein (LBP) and CD14 and subsequently
to the TLR4/MD2 receptor complex [11,12]. Recombi-
nant forms of naturally occurring AMP have been admi-
nistered i.v. in sepsis without causing harm [13], but
most synthetic AMPs were applied locally probably due
to intrinsic toxicity [14,15]. The response to external sti-
mulation was significantly improved in septic mice trea-
ted with SALP 19-2.5 (Table 3).
In addition, inhibition of pro-inflammatory cytokine
release may provide a suitable approach to anti-infective
therapy [14]. The naturally derived bactericidal/perme-
ability increasing (BPI) protein was reported to attenuate
inflammation and systemic effects caused by endotoxin
release [5]. In contrast, designed AMP may exert a
broader range of anti-microbial activity and may be
optimized with respect to binding capacity, thus allow-
ing smaller amounts of infused peptide.
Constitutive AMP expression levels may be enhanced by
cytokines, such as IL-6 [16]. In contrast, by employing syn-
thetic anti-inflammatory peptides, we could demonstrate a
significant (85%) reduction of serum IL-6 24 hours after
CLP following therapy with Pep 2.5 (Figure 2). The two
other peptides (Pep 4 and Pep 8) differed in their ability to
neutralize LPS and had a weaker effect on cytokine levels
after challenge [4]. The different SALPs displayed the fol-
lowing sequence in inhibition efficiency: Pep 2.5 (very
high) > Pep 4 (medium) > Pep 8 (low). These findings are
in line with our results showing a non-significant decrease
of IL-6 after CLP with Pep 4 (-43%) or Pep 8 (-4%) treat-
ment (Figure 2). The different effects of the single peptides
can be explained by their varying strengths of binding to
bacterial cell envelope compounds. To optimize this bind-
ing, the length of the peptide, the number of basic amino
acids, and the number of hydrophobic amino acids have
been adapted to the physico-chemistry of LPS and LP.
The peptides were designed and constructed with this
Figure 6 CD14 expression in liver tissue after 24 hours of
sepsis. Sham (N 10) = Sham operation with vehicle infusion; Sepsis-
control (N = 10) = Sepsis with vehicle infusion; polyB (N = 10) =
Sepsis with PolymyxinB infusion; Pep 2.5 (N = 10) = Sepsis with
peptide 19-2.5 infusion; Pep 4 (N = 10) = Sepsis with peptide 19-4
infusion; Pep 8 (N = 10) = Sepsis with peptide 19-8 infusion; Data
given as mean ± SEM; *P < 0.05 versus sham. SEM, standard error of
the mean.
Figure 7 CD14 expression in kidney tissue after 24 hours of
sepsis. Sham (N = 10) = Sham operation with vehicle infusion;
Sepsis-control (N = 10) = Sepsis with vehicle infusion; polyB (N =
10) = Sepsis with PolymyxinB infusion; Pep 2.5 (N = 10) = Sepsis
with peptide 19-2.5 infusion; Pep 4 (N = 10) = Sepsis with peptide
19-4 infusion; Pep 8 (N = 10) = Sepsis with peptide 19-8 infusion;
Data given as mean ± SEM; *P < 0.05 versus sham. SEM, standard
error of the mean.
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aim, and Pep 2.5 was found to represent an optimum. The
designed peptides act via a Coulomb interaction between
peptide and LPS and a hydrophobic interaction of the
amino acids at the C-terminal end of the peptides with the
acyl chain moiety of LPS or LP. Both steps are necessary
for this interaction [4]. Beside the LPS-binding capacity,
the cytokine decrease may be partly explained by better
bacterial clearance in blood and organ tissue after admin-
istration of AMP as demonstrated previously [17,18].
After incorporation in cell membranes, the peptides
apparently act at the site of membrane receptors, such
as CD14 [19]. Within organ tissue, CD14 is expressed
by macrophages, dendritic cells, epithelial cells, endothe-
lial cells and fibroblasts and is released into the cell
supernatant or attached to the plasma membrane by a
Glycosylphosphatidylinositol (GPI) anchor [20]. CD14
significantly contributes to the TLR4-mediated LPS
recognition but is also involved in the stimulation by
TLR2 ligands. As we used a model of polymicrobial
(gram-positive and-negative) sepsis, changes in CD14
expression, increased by TLR4- and/or TLR2-mediated
signaling, may reflect infection with both gram stain
groups. Expression of CD14 itself is upregulated by
innate immune stimulation and, thus, can be used to
analyze both innate immune signaling and immune cell
recruitment. Pep 2.5 therapy in CLP-induced sepsis
decreased CD14 expression in lung tissue, indicating
reduced innate immune stimulation and/or reduced
immune cell recruitment as a consequence of Pep 2.5
mediated inhibition of inflammation (Figure 4).
The importance of CD14 for a pro-inflammatory
response in heart tissue was emphasized in a mouse
model, where CD14-deficient mice experienced no ven-
tricular dysfunction and decreased cytokine mRNA
expression after LPS challenge [21]. Compared to the
sepsis-control group we could also demonstrate signifi-
cantly decreased CD14-expression in heart tissue after
Pep 2.5 therapy (Figure 3), whereas no difference was
noted in liver tissue between the groups examined (Fig-
ure 6). In contrast, hepatic CD14 was previously found
to be increased after LPS injection [22], and following
CLP [23]. Also, repeated injections of recombinant bac-
tericidal/permeability-increasing protein (rBPI21) in
early sepsis after CLP in rats led to a significant
decrease in CD14mRNA in liver, lung and kidneys [24].
Both BPI and Pep 2.5 contain a high-affinity binding
domain for the lipid A component of endotoxin. Our
peptides and BPI block endotoxin binding to CD14,
thus inhibiting cytokine release [19,25].
Differences of mouse strains, experimental protocols
and the severity of CLP may influence these results.
A strong increase of CD14 after LPS challenge and in
CLP sepsis was noted in kidney tissue, predominantly in
proximal tubular cells [24,26]. We could demonstrate
the strongest CD14 upregulation of all investigated
organs in kidney tissue. However, only non-significantly
decreased expression of CD14 was noted in all treat-
ment groups (Figure 7). Why the immunomodulatory
activity of Pep 2.5 did not exert a significant effect in
renal tissue is unclear. Since the anti-inflammatory
effects of the tested SALPs are dose-dependent [4], one
possible explanation might be the limited penetration
into renal tissue. In contrast to liver and kidney, spleen
tissue displayed a significant reduction of CD14 expres-
sion after Pep 2.5 treatment but not with the other
tested peptides compared to controls (Figure 5). Since
LPS-challenge resulted in an increase in cytokines in the
spleen [27], Pep 2.5 might contribute to reduce the
inflammatory reaction in spleen tissue.
Polymyxin B is considered the most potent anti-endo-
toxin agent and is used in experimental studies to com-
pare endotoxin-neutralizing effects [28]. Furthermore,
CD14 is not only involved in Gram-negative infection,
but plays a role in lipoteichoic acid (LTA)-induced cyto-
kine release by Gram-positive pathogens [29]. In our
model we could identify gram-positive and -negative
bloodstream invasion by PCR based diagnosis (Methicil-
lin-susceptible Staphylococcus aureus, Escherichia coli,
and Enterococcus faecalis, VYOO®, SIRS-Lab, Jena, Ger-
many). Pep 2.5 therapy resulted in less cytokine release
than polymyxin B and reduced CD14 expression in all
organ tissues, suggesting activity also against Gram-posi-
tive pathogens in our model.
Yet, there are some limitations of our study. First, the
use of a mouse model limits the transferability to
human sepsis. Second, the 24-hour duration of our
model describes only the early phase of sepsis. The
results may differ in later stages of sepsis after a first
improvement. Moreover, we did not provide outcome
data to prove a sustained effect of continuous SALP
infusion. Third, the infusion of the tested peptides
started right after the sepsis stimulus, reflecting more
experimental than real conditions. Furthermore, the
underlying mechanisms of the effects of the tested
SALP’s beyond isolated gram-negative sepsis remain to
be determined. An investigation on peptide activity
against viruses showed that the peptides used in our
study bind to heparan sulfate (HS) moieties on cells and
may inhibit infection with enveloped viruses [30]. The
mode of action the SALPs presented here is, therefore,
not restricted to the binding to the lipid A moiety of
LPS. The SALP’s mode of action is innovative because it
does not solely block the pro-inflammatory cascade by
inactivating LPS-mediated cytokine release but possibly
counters inflammation in organ tissue by interacting
with HS as part of the glycocalyx. Thus, we will further
investigate peptide-HS interaction in bacterial infection
to clarify a general interaction.
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Conclusions
Using a widely used mouse model of polymicrobial sep-
sis, we analyzed the clinical efficacy of the newly devel-
oped SALP 19-2.5. Continuous Pep 2.5 infusion
significantly enhanced the activity and decreased plasma
levels of pro-inflammatory cytokines as well as CD14
mRNA tissue expression compared to untreated controls.
Thus, SALP 19-2.5 may have the potential for further
development as a tool in anti-infection treatment.
Key messages
• Continuous parenteral administration of SALP is
able to reduce sepsis-induced cytokine release.
• SALPs differ in their ability to decrease cytokine
levels after sepsis challenge according to their amino
acid sequence.
• CD14 mRNA tissue expression is significantly
decreased by continuously infused SALP compared
to untreated controls.
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